Last reviewed · How we verify

Fluarix vaccine

GlaxoSmithKline · FDA-approved active Biologic Quality 5/100

Fluarix vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently FDA-approved.

Fluarix, a vaccine marketed by GlaxoSmithKline, holds a significant position in the influenza vaccine market. A key strength is the protection of its key composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk is the competitive landscape, with multiple other influenza vaccines available from different manufacturers.

At a glance

Generic nameFluarix vaccine
SponsorGlaxoSmithKline
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fluarix vaccine

What is Fluarix vaccine?

Fluarix vaccine is a Biologic drug developed by GlaxoSmithKline.

Who makes Fluarix vaccine?

Fluarix vaccine is developed and marketed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is Fluarix vaccine in?

Fluarix vaccine is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing